PeopleImages
- Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector.
- Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator.
- In this article you will find out who is more promising for long-term investors.
This article is the first in a series of comparative analyses between two pharmaceutical companies. These articles will compare two stocks that focus on specific therapeutic areas. It is my intention to publish one article each week over the next four weeks.
However, in the case of Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) (NEOE:PFE:CA), the analysis of which I will present later, their business is not focused only on a specific area.
So, in addition to selling vaccines, these two giants are engaged in the development and commercialization of drugs intended to treat a wide range of diseases, from cancer to rare diseases.
READ FULL ARTICLE HERE!
